🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07205471
Recruiting Not applicable

Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients

NCT07205471 · tracked via the Priya Life Science China tracker
Sponsor
Northern Jiangsu People's Hospital
Phase
Not applicable
Started
2025-09-24
Last updated
2025-10-03

Condition(s) studied

Cirrhoses, LiverSplenectomy; StatusPartial

Investigational drug(s) / intervention(s)

Laparoscopic Partial Splenectomy

Laparoscopic Partial Splenectomy: The laparoscopic partial splenectomy technique involved preserving the short gastric vessels and the splenic suspensory ligament, with resection conducted along the demarcation line.

Study summary

In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance postoperative immune function and thereby improve patient outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism * gastroesophageal variceal bleeding * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Human immunodeficiency virus (HIV) infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Medical College of Yangzhou University Yangzhou Jiangsu Recruiting

More Northern Jiangsu People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07205471 on ClinicalTrials.gov ↗ ← All trials in China